^
Association details:
| Biomarker: | ALK L1152R + EGFR mutation |
|---|---|
| Cancer: | Lung Cancer |
| Drug Class: | EGFR inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations
Published date:
10/15/2021
Excerpt:
Patients with concurrent EGFR and ALK mutations were included in this study, which analyzed mutation profiles and treatment histories....In addition, the mPFS of patients with ALK-L1152R/EGFR (n = 2) was significantly shorter than that of patients with other co-mutation genotypes (n = 7, one patient had unclear PFS information, mPFS of 18.2 vs 4 months, p = 0.004...
DOI:
https://doi.org/10.1186/s12885-021-08824-2
